StockData
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA) stock

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.70−0.03 (-1.73%)

Close on Nov 18, 2026Market cap $4.75MP/E –Yield –

Processa Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Processa Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2024 was -$11.25M. For fiscal 2024 it was -$11.25M. The highest annual figure on record is -$873.31K in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$11.25M–
FY2023Dec 31, 2023-$8.07M–
FY2017Dec 31, 2017-$1.68M–
FY2016Dec 31, 2016-$2.18M–
FY2015Dec 31, 2015-$873.31K–
FY2014Dec 31, 2014-$2.70M–
FY2013Dec 31, 2013-$2.57M–
FY2012Dec 31, 2012-$2.23M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$2.25M–
Q4 FY2023Dec 31, 2023-$2.12M–
Q1 FY2017Mar 31, 2017-$59.58K–

More Processa Pharmaceuticals figures

See a number that looks wrong?